King Faisal Specialist Hospital and Research Center to Host Advanced Therapies Forum
Get ready for an exciting event at the King Faisal Specialist Hospital and Research Center (KFSH&RC) in Riyadh! The Advanced Therapies Forum is coming your way on June 23-24, as reported by the Saudi Press Agency.
Collaboration and Innovation
This forum will bring together 30 representatives from government organizations, academic institutions, and advanced therapy manufacturing companies. The main goal is to create a collaborative environment where industrial partners can showcase their cutting-edge research and form strategic alliances with healthcare institutions.
Building Bridges
The agenda of the forum is all about building bridges between academic healthcare institutions, industry stakeholders, funding agencies, investors, regulators, and government agencies. The focus will be on increasing the number of clinical research studies in the fields of T-cell therapy and gene therapy.
Opportunities for Industrial Partners
Pharmaceutical companies, big and small, will have the chance to explore launching clinical research initiatives at KFSH&RC. This is an incredible opportunity to make a difference in the field of advanced therapies.
Exciting Lineup
The forum will feature 15 keynote speeches, over 30 presentations on ongoing projects by industry leaders, five panel discussions, and numerous other sessions. The ultimate goal is to shape the future of advanced therapies in the Kingdom and localize manufacturing technology for cellular and gene therapies.
Success Stories at KFSH&RC
KFSH&RC has been a beacon of hope for patients with limited treatment options. The hospital has successfully treated over 120 individuals using genetically modified immune cells. From treating the first child in the region with T-cells to applying advanced gene therapy for hereditary hemophilia, the hospital continues to make groundbreaking strides in the field.
Global Growth in Advanced Therapies
Experts predict that the global cell and gene therapy market will exceed $50 billion annually by 2027, surpassing the traditional pharmaceutical industry. With over 30 approved therapies and more than 2 million patients expected to benefit from T-cell therapy in the next decade, the future of advanced therapies looks bright.